Table 2.
Time-matched QTcI differences between baseline-subtracted semaglutide 1.5 mg and placebo during the 48 h after dosing
| Time point after dosing (h) | Estimated treatment difference semaglutide vs. placebo (ms) (N = 76 each group) | 90% Confidence interval | P valuea |
|---|---|---|---|
| 0 | – 3.2 | – 6.6; 0.3 | < 0.0001 |
| 12 | – 3.4 | – 7.0; 0.3 | < 0.0001 |
| 18 | – 5.1 | – 8.8; – 1.4 | < 0.0001 |
| 24 | – 4.8 | – 8.3; – 1.3 | < 0.0001 |
| 25 | – 4.3 | – 7.8; – 0.8 | < 0.0001 |
| 26 | – 5.8 | – 9.2; – 2.5 | < 0.0001 |
| 27 | – 5.3 | – 8.7; – 1.8 | < 0.0001 |
| 30 | – 3.9 | – 7.1; – 0.6 | < 0.0001 |
| 36 | – 5.9 | – 9.5; – 2.3 | < 0.0001 |
| 42 | – 6.6 | – 10.1; – 3.0 | < 0.0001 |
| 48 | – 5.1 | – 8.3; – 2.0 | < 0.0001 |
N number of subjects contributing to the analysis, QTcI QT interval corrected individually for heart rate
aP values are for a one-sided test of a mean difference of > 10 ms